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Abstract 
Hepatic tryptophan 2,3-dioxygenase (TDO) is one of the rate-limiting enzymes in tryptophan catabolism and 
plays an important role in regulating the physiological flux of tryptophan into relevant metabolic pathways. In 
this study, we determined the effect of the non-steroidal anti-inflammatory agents, tolmetin and sulindac, on rat 
liver TDO activity and the subsequent changes in the hippocampal and striatal neurotransmitter levels. The 
amount of melatonin produced by the pineal gland was also measured using high performance liquid 
chromatography (HPLC). Treatment of rats with tolmetin or sulindac (5 mg/kg/bd for 5 days) significantly 
inhibited liver TDO activity. The results show that whilst tolmetin and sulindac increase serotonin levels in the 
hippocampus, these agents also significantly reduce dopamine levels in the striatum. Tolmetin, but not sulindac, 
increased the amount of melatonin produced by the pineal gland. The results of this study suggest that whilst 
tolmetin and sulindac may be beneficial for patients suffering from depression, these agents also have the 
potential to induce adverse effects in patients suffering with neurological disorders such as Parkinson's disease. 
Introduction 
Hepatic tryptophan 2,3-dioxygenase (TDO) is the rate-limiting enzyme in the oxidative breakdown of tryptophan 
to kynurenine in the body. Its activity determines the relative tryptophan flux into the serotonergic and 
kynurenine pathways. Hepatic TDO is specific for tryptophan as the substrate (Hayaishi, 1980).  
Tryptophan is hydroxylated to 5-hydroxytryptophan by tryptophan hydroxylase, which is present in high 
concentrations in the pineal gland, and is the rate-limiting step in the synthesis of 5-hydroxytryptamine (5-HT) 
(Lovenberg et al., 1968). It is the amount of tryptophan available and not the enzyme activity that influences the 
rate of the reaction (Deguchi and Barchas, 1972 and Bensinger et al., 1974). In the pineal gland there is sufficient 
aromatic amino acid decarboxylase, which decarboxylates 5-hydroxytryptophan to produce 5-HT.  
Serotonin is an important regulator in a wide range of physiological and biochemical processes in vertebrates. 
Serotonin is involved in the maintenance of circadian rhythmic functions, blood pressure regulation, acts as a 
neurotransmitter at central and peripheral regions (Kema et al., 2000), and is known to act as its own trophic 
factor (Mohanakumar et al., 1995). Alterations in brain serotonin levels are known to result in mood disorders, 
particularly depression (van Praag, 1982). Serotonin can be N-acetylated to form N-acetyl serotonin, in a reaction 
catalyzed by the enzyme N-acetyltransferase. In most circumstances this is the rate-limiting step in melatonin 
synthesis (Klein et al., 1997). The 5-hydroxy group of N-acetylserotonin is O-methylated in the presence of 
hydroxyl-O-methyltransferase to form melatonin.  
In the last several years, melatonin, the chief secretory product of the pineal gland (Reiter, 1991), has been found 
to be both a direct free radical scavenger and an indirect antioxidant (Hardeland et al., 1995, Hardeland, 1997, 
Reiter et al., 1995 and Reiter et al., 1997), in addition to its function as a neurohormone. Because of these actions, 
melatonin has been pharmacologically tested for its ability to reduce oxidative damage in a variety of 
experimental neurological processes and has been found to be highly effective in this respect (Reiter et al., 1997 
and Reiter, 1998). Melatonin is both lipid (Costa et al., 1995) and water soluble (Shida et al., 1994), although its 
lipid solubility is greater and has the ability to traverse almost every organ in the body (Reiter, 1995). It has been 
demonstrated to be a powerful antioxidant and free radical scavenger (Tan et al., 1993) and reduce oxidative 
damage in the central nervous system (Reiter, 1998).  
 
 
Neuroinflammation has been implicated in the pathogenesis of neurological disorders such as Alzheimer's and 
Parkinson's disease (McGeer, 1988, Castano et al., 1998, Langston et al., 1999 and Cicchetti et al., 2002). 
Although non-steroidal anti-inflammatory drugs (NSAIDS) may offer neuroprotection via anti-inflammatory 
action, other mechanisms may also be involved at the neurotransmitter level (Mohanakumar et al., 2000 and 
Sairam et al., 2003). Any drug used for the treatment of whichever disease should not aggravate the underlying 
pathology. In this study, we determined the effects of tolmetin and sulindac, commonly used NSAIDS for pain, 
inflammation, arthritis and rheumatoid arthritis, on brain neurotransmitter levels in the hippocampus and striatum. 
The effect of these NSAIDS on rat liver TDO activity and biogenic amines such as serotonin, dopamine and their 
metabolites as well as the amount of melatonin produced by the pineal gland were determined.  
Materials and methods 
Chemicals 
Tolmetin, sulindac, melatonin, L-tryptophan, hematin, dopamine (DA), serotonin, 5-hydroxy-3-indoleacetic acid 
(5-HIAA) and dihydroxyphenyl acetic acid, (DOPAC), phosphoric acid (PA) and octane sulphonate (OSA) were 
purchased from Sigma Chemicals Company, St Louis, MO, U.S.A. Trichloroacetic acid (TCA), triethylamine 
(TEA) and perchloric acid (HCLO4) were obtained from Saarchem, Johannesburg, ethylenediamine tetraacetic 
acid (EDTA) was purchased from HOLPRO Analytics, (PTY) LTD, Johannesburg, South Africa. HPLC grade, 
acetonitrile (ACN), methanol (MeOH) and chloroform were purchased from BDH Laboratory Supplies, Poole, 
England. Minimum Essential Medium (MEM) was purchased from Highveld Biologicals, South Africa. All other 
reagents were of the highest quality available.  
Animals 
Adult male rats of the Wistar strain, weighing between 250–300 g were purchased from South African Institute 
for Medical Research (Johannesburg, South Africa). The animals were housed in a controlled environment with a 
12-h light: dark cycle, and were given access to food and water ad libitum. The Rhodes University animal ethics 
committee approved protocols for the experiments.  
Methods 
Treatment regimes 
Animals were divided into three groups A, B and C. Group A served as the control while groups B and C 
received either tolmetin or sulindac at a dose of 5 mg/kg/bd for 5 days. On the 6th day animals were killed by 
neck fracture. The livers were removed, perfused with cold normal saline and stored at − 70 °C until use. The 
hippocamppi and striatum were dissected from the brain, frozen in liquid nitrogen and stored at − 70 °C until use. 
The pineal gland from each rat was removed and incubated for 24 h at 37 °C in 50 µl of MEM that was 
supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml) and amphotericin B (2.5 µg/ml) in a sterile 
humidified incubator.  
Liver tryptophan 2,3-dioxygenase activity 
The activity of the enzyme was determined according to a modified method previously described by Badawy and 
Evans (1975). The livers were thawed, chopped into fine pieces and homogenised with 60 ml 140 mM 
KCl/2.5 mM NaOH using a glass–teflon hand held homogenizer. The homogenate was sonicated for a period of 
2 min at 30 s intervals for complete release of enzymes from the cells. Finally 0.2 M sodium phosphate buffer pH 
7.0 was used to make up the volume required to yield a 10% w/v homogenate. The entire procedure, where 
possible, was conducted on ice. An aliquot of 15 ml homogenate was added to a flask containing 12.5 ml water. 
An aliquot of haematin (100 µl) at a final concentration of 2 µM (Badawy and Evans, 1975) was added to samples 
that were used to determine the total activity of the enzyme. This was stirred for 1 min to allow for the activation 
of the enzyme. Finally, 2.5 ml of 0.03 M L-tryptophan was added to all flasks and gently stirred. The assay was 
conducted in triplicate. Aliquots of 3 ml of the assay mixture was transferred to test tubes, stoppered under 
carbogen and incubated for 1 h at 37 °C in an oscillating water bath. The enzyme activity was determined in the 
absence and presence of haematin in order to determine the activity of the holo- and apoenzymes of TDO. The 
apoenzyme in isolation is inactive but in the presence of haematin becomes fully active. The holoenzyme activity 
was measured in the absence of haematin while the total activity was measured in the presence of added 
haematin. The reaction was terminated with the addition of 2 ml of 0.9 M TCA to the reaction mixture and 
incubated for 2–4 min. The mixture was filtered through a Whatman no. 1 filter paper. Filtrate (2.5 ml) was added 
to 1.5 ml of 0.6 M NaOH and vortexed. The kynurenine present in the solution was measured at 365 nm 
spectrophotometrically using the molar extinction coefficient of kynurenine: ε = 4540 M− 1.cm− 1. The blank 
consisted of 2 ml TCA and 1.5 ml NaOH. The TDO activity was expressed as nmol/mg protein/h. Protein 
estimation was performed using the method described by Lowry et al. (1951).  
High performance liquid chromatography (HPLC)–electrochemical evaluation of biogenic 
amines 
Instrumentation and chromatographic conditions 
Samples were analyzed on an isocratic HPLC coupled to an electrochemical detector. The chromatographic 
system consisted of a Waters Millipore Model 510 pump, a Waters electrochemical detector and a Rikadenki 
chart recorder. Samples were introduced into the system using a Rheodyne Model 7725i fixed loop injector, fitted 
with a 20 µl loop. Separation was achieved using a C18 (Waters Spherisorb©, 5 µm, 250 × 4.6 mm o.d.s. 2 
column). The mobile phase consisted of 13% ACN, 8.32 mM OSA, 0.27 mM, EDTA, 0.4–0.45% TEA and 0.2–
0.25% PA (v/v) and made to 1000 ml using Milli-Q water. Mobile phase was degassed twice using a 0.45 µM 
membrane filter prior to use. The flow rate was set at 0.8 ml/min and the electrochemical detector was set at a 
potential of + 0.74 V.  
Biochemical analyses of biogenic amines 
5-HT, DA, 5-HIAA and DOPAC were measured according to a similar method described by Muralikrishnan and 
Mohanakumar (1998). The frozen hippocamppi and striatum were thawed and weighed, deproteinised in 10% w/v 
of ice-cold HCLO4 (0.1 M) containing 0.01% EDTA. These samples were thereafter sonicated at 50 Hz for 30 s 
using an ultrasonic cell disruptor. The homogenates were kept at 4 °C on ice for approximately 20 min prior to 
centrifugation at 10,000 ×g for 10 min. The supernatant (10 µl) was directly injected into the HPLC–
electrochemical detector system for analyses. Results are expressed as pmol/mg tissue.  
HPLC–UV determination of the amount of melatonin produced by the pineal gland 
Instrumentation and chromatographic conditions 
Instrumentation used was as described above; however a Waters 2487 dual absorbance UV–VIS detector was 
used instead of an electrochemical detector. The mobile phase consisted of ACN:MeOH:H20 (4:1:5) at a flow rate 
of 1 ml/min. The detector wavelength was set at 304 nm and the injection volume was 20 µl. The Breeze software 
was used to control the HPLC system and to acquire and analyze data.  
Method validation 
A stock solution of melatonin (0.1 mg/ml) was freshly prepared for each test by weighing melatonin and 
dissolving it in mobile phase. Dilutions of this stock solution were made appropriately for the concentration range 
to be studied. Samples for the assessment of linearity and precision were prepared by serial dilution of the stock 
solution to yield concentrations over the range 100–500 ng/ml. In addition, two concentrations within the 
calibration range were prepared independently for use as accuracy standards. The limits of quantification and 
detection were also determined. Specificity was determined by mass spectrometry. Quantitative determination of 
melatonin was made by comparison of peak heights using known concentrations of melatonin.  
 
 
 
Extraction efficiency 
To 40 µl of MEM, 10 µl of mobile phase containing known amounts of melatonin was added. The final 
concentrations of melatonin were 200, 300 and 400 ng/ml. To this, 1 ml of chloroform was added and vortexed. 
An aliquot of 0.5 ml of the chloroform was removed and evaporated to dryness on a hot water bath. The residue 
(melatonin) was dissolved in 50 µl of mobile phase and 20 µl was injected onto the column for analyses.  
Amount of melatonin produced by the pineal gland 
After the pineal glands had been incubated in the 50 µl of MEM at 37 °C for 24 h, the glands were removed and 
1 ml of chloroform was added and vortexed. The rest of the experiment was conducted as described above. 
Results are represented as amount of melatonin produced per pineal in 24 h and are shown as uncorrected values.  
Mass spectrometry 
The HPLC system consisted of a spectrasystem AS300 autosampler, a spectrasystem UV200 detector and a 
spectrasystem P2000 pump. The mobile phase consisted of A: ammonium acetate made to pH 3 using formic 
acid, and B: methanol. A linear gradient from 15% to 90% MeOH was run over 17 min. Separation was achieved 
on a C18 (Waters Spherisorb©, 5 µm, 250 × 4.6 mm o.d.s. 2 column). The LC instrument was interfaced with a 
Finnigan MAT LCQ mass spectrometer equipped with an electrospray ionization (ESI) source. The mass 
spectrometer was configured in the positive ion mode and to use selective ion monitoring (SIM) for the melatonin 
parent ion in the m/z range 60–240. The mass spectrometer parameters were as follows: the nebulizer nitrogen gas 
flow rate was set at 80, discharge voltage of 4.5 kV, the capillary temperature was set at 220 °C, the capillary 
voltage was 20 V and the discharge current was 5 µA. The LC–MS workstation Xcalibur, version 1.3, was used 
for system control and data acquisition.  
Statistical analyses 
Results were analyzed using a one-way analysis of the variance (ANOVA) followed by the Student–Newman–
Keuls Multiple Range Test. The level of significance was accepted at p < 0.05 (Zar, 1974).  
Results 
Fig. 1 shows that both the NSAIDS, tolmetin and sulindac, inhibit the holoenzyme but have no effect on the 
apoenzyme, and both agents significantly reduced the total TDO activity.  
 
 
Fig. 1. Effect of tolmetin and sulindac (5 mg/kg/bd for 5 days) on liver TDO activity. Each bar represents the mean ± SD (n = 6). 
ns(p > 0.05), (p < 0.05) and (p < 0.01) as compared to controls.  
 
Tolmetin and sulindac treated animals (5 mg/kg/bd for 5 days) show an increase in the levels of serotonin 
(6.12 ± 0.25 and 5.84 ± 0.20 pmol/mg tissue respectively) in the hippocampus compared to controls 
(5.19 ± 0.24 pmol/mg tissue) (see Fig. 2). Tolmetin treated animals also show an increase in the 5-HIAA levels in 
the hippocampus. DA and DOPAC levels in the hippocampus demonstrated no significant changes after 
treatment. As shown in Fig. 3, in the striatum, tolmetin and sulindac significantly reduces the DA levels 
(60.85 ± 3.18 and 68.87 ± 5.19 pmol/mg tissue respectively) when compared to controls (72.70 ± 2.94 pmol/mg 
tissue). DOPAC levels were significantly higher in tolmetin treated animals but not the sulindac treated animals.  
 
 
Fig. 2. Effect of tolmetin and sulindac (5 mg/kg/bd for 5 days) on rat hippocampal biogenic amine levels. Each bar represents the 
mean ± SD (n = 5). ns(p > 0.05), (p < 0.01) and (p < 0.001) as compared to controls.  
 
 
 
Fig. 3. Effect of tolmetin and sulindac (5 mg/kg/bd for 5 days) on rat striatum biogenic amine levels. Each bar represents the mean ± SD 
(n = 5). ns(p> 0.05), (p < 0.05) and (p < 0.01) as compared to controls.  
Chromatograms of melatonin obtained show symmetrical peaks which were resolved from the solvent front with 
a retention time of 4.1 min. Regression analysis shows that the concentration versus peak height is linear over the 
range studied i.e.100–500 ng/ml (r2 = 0.9998). The limits of detection (LOD) and limits of quantification (LOQ) 
were 5 ng/ml and 15 ng/ml respectively. Inter- and intra-assay precision was determined by calculating the 
relative standard deviation (RSD) of peak heights of the calibration standards (n = 5) and is reported as RSD %. 
The intra-assay precision show RSD % values of 0.86%–2.28% and the inter-assay precision show RSD % values 
of 0.58%–2.11%. Approximately 80% of the melatonin was extracted from 50 µl of MEM (containing 200, 300 
or 400 ng/ml melatonin) using 1 ml of chloroform. The standard sample of melatonin and the extract from the 
pineal glands showed base peaks at m/z 174 (mass spectral data not shown). It has been suggested (Xie et al., 
1998), that this molecular ion is formed by the loss of the HN COH–CH3 fragment from the protonated parent 
molecule with the formation of a four-membered ring from the side chain.  
 As shown in Fig. 4, tolmetin but not sulindac, significantly (p < 0.05) increases melatonin synthesis. Controls 
release 11.96 ± 0.13 ng of melatonin in 24 h while tolmetin and sulindac treated animals release 12.33 ± 0.14 and 
11.99 ± 0.17 ng of melatonin in 24 h respectively.  
 
 
Fig. 4. Effect of tolmetin and sulindac treatment on melatonin synthesis in the rat pineal gland. Each bar represents the mean ± SD 
(n = 5). ns(p > 0.05) and (p < 0.05) when compared to controls.  
Discussion 
Tryptophan is an essential amino acid having various important biological functions. One of its biochemical 
pathways is known as the tryptophan–niacin or kynurenine pathway (Musajo and Benassi, 1964, Price et al., 1965 
and Wolf, 1974). In adults about 90% of dietary tryptophan is metabolized along this pathway (Wolf, 1974). It 
has been shown that the administration of antidepressant drugs, including tricyclic antidepressants, results in the 
inhibition of liver TDO resulting in the elevation of brain tryptophan and serotonin concentrations (Hardeland and 
Rensing, 1968 and Walsh and Daya, 1998). In the present study, tolmetin and sulindac both inhibit the total liver 
TDO enzyme activity. Both agents inhibit the holoenzyme, resulting in the inhibition observed in total enzyme 
activity. The reason why these agents do not alter apoenzyme activity needs further investigation. One possibility 
is that these agents do not alter the ability of heme to bind to the active sites. This was accompanied by a 
significant increase in 5-HT in the hippocampus. Despite the differences, inhibition of TDO could be one possible 
mechanism via which both agents increased serotonin levels in the hippocampus.  
Depression is a complex condition involving abnormalities in the sympathetic nervous system as well as the 
endocrine and immune systems (Szelenyi and Selmeczy, 2002). In the present study, much attention was focused 
on the hippocampus and striatum, where monoamines are present, since these regions play crucial roles in 
behavioral functions such as learning, memory and emotion, all of which may be affected in depression 
(Butterweck et al., 2002). The results show that both tolmetin and sulindac increase 5-HT levels in the 
hippocampus but not in the striatum implying that these agents may have potential use in patients suffering from 
depression. Inhibition of liver TDO is known to result in the increased circulating levels of tryptophan, making 
more of this amino acid available for uptake into the brain where it is converted to 5-HT (Curzon, 1969 and 
Curzon and Bridges, 1970).  
Dopamine (DA) has received a great deal of attention in the mammalian CNS (Albin et al., 1989, Williams and 
Goldman-Rakic, 1995 and Greengard et al., 1999). This neurotransmitter plays an important role in multiple 
functions such as movement, memory, mental and psychological activities (Albin et al., 1989, Kalivas and 
Stewart, 1991, Williams and Goldman-Rakic, 1995 and Knable and Weinberger, 1997). Abnormalities of DA 
signaling may result in several neurological disorders such as Parkinson's disease, epilepsy, schizophrenia and 
drug abuse (Kalivas and Stewart, 1991, Koob, 1992, Koob and Le Moal, 1997 and Nestler and Aghajanian, 
1997). Parkinson's disease is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, 
leading to a reduction in DA levels in the striatum (Deumens et al., 2002). This study shows that both tolmetin 
and sulindac reduce DA levels in the striatum, suggesting that these NSAIDs may have the potential to exacerbate 
or induce DA-deficient neurological disorders.  
NSAIDs are thought to exert most of their effects via prostaglandin synthesis inhibition (Vane, 1971 and Flower 
and Vane, 1972) and it is known that prostaglandins markedly enhance melatonin synthesis at night (Cardinali et 
al., 1979, Cardinali et al., 1982 and Voisin et al., 1993). Thus, NSAIDS have the ability to reduce melatonin 
synthesis. For example, it has been shown that NSAIDs such as aspirin (Murphy et al., 1986) and ibuprofen 
(Surrall et al., 1987 and Murphy et al., 1986) reduce melatonin synthesis in humans. However, in the present 
study, tolmetin, but not sulindac, increases the amount of melatonin produced by the rat pineal gland. It is 
unlikely that the rise in melatonin induced by tolmetin is a consequence of inhibition of TDO in the liver as it has 
been shown (Daya et al., 1989), that such inhibition does not alter melatonin levels. A possible reason for the 
tolmetin-induced increase in melatonin synthesis could be a direct effect of this drug on the melatonin synthesis 
pathway in the pineal gland.  
Conclusion 
Tolmetin and sulindac inhibit TDO with a concomitant increase in 5-HT levels in the hippocampus, suggesting 
that theses agents may be beneficial for patients suffering from depression. However, these agents simultaneously 
reduce DA levels in the striatum and thus do have implications in Parkinson's patients.  
 
Acknowledgments 
The authors would like to thank the National Research Foundation and Rhodes University for their funding, as 
well as Sally and Dave Morley for their technical support.  
 
References 
Albin et al., 1989 R.L. Albin, A. Young and J.B. Penney, The functional anatomy of basal ganglia disorders, 
Trends in Neurosciences 12 (1989), pp. 366–375.  
Badawy and Evans, 1975 A.A.B. Badawy and M. Evans, The regulation of rat liver tryptophan pyrrolase by its 
cofactor haem. Experiments with haematin and 5-aminolaevulinate and comparison with the substrate and 
hormonal mechanisms, Biochemical Journal 150 (1975), pp. 511–520.  
Bensinger et al., 1974 R.E. Bensinger, D.C. Klein, J.L. Weller and W. Lovenberg, Radiometric assay of total 
tryptophan hydroxylation by intact cultured pineal glands, Journal of Neurochemistry 23 (1974), pp. 111–117.  
Butterweck et al., 2002 V. Butterweck, T. Bockers, B. Korte, W. Bittkowski and H. Winterhoff, Long-term 
effects of St. John's wort and hypericin on monoaminelevels in rat hypothalamus and hippocampus, Brain 
Research 930 (2002), pp. 21–29 
Cardinali et al., 1979 D.P. Cardinali, N.M. Ritta, N. Speziale and M.F. Gimeno, Release and specific binding of 
prostaglandins in bovine pineal glands, Prostaglandins 18 (1979), pp. 577–580.  
Cardinali et al., 1982 D.P. Cardinali, N.M. Ritta, E. Pereyra and C.G. Solveyra, Role of prostaglandins in rat 
pineal neuroeffector junction. Changes in melatonin and norepinephrine release in vitro, Endocrinology 111 
(1982), pp. 530–534.  
Castano et al., 1998 A. Castano, A.J. Herrera, J. Cano and A. Machado, Lipopolysaccharide intranigral injection 
induces inflammatory reaction and damage in nigrostriatal dopaminergic system, Journal of Neurochemistry 70 
(1998), pp. 1584–1592.  
Cicchetti et al., 2002 F. Cicchetti, A.L. Brownell, K. Williams, Y.I. Chen, E. Livni and O. Isacson, 
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats 
monitored by immunohistochemistry and PET imaging, European Journal of Neuroscience 15 (2002), pp. 991–
998.  
Costa et al., 1995 E.J. Costa, R.H. Lopes and M.T. Lamy-Freund, Permeability of pure lipid bilayers to 
melatonin, Journal of Pineal Research 19 (1995), pp. 123–126.  
Curzon, 1969 G. Curzon, Tryptophan pyrrolase—a biochemical factor in depressive illness?, British Journal of 
Psychiatry 115 (1969), pp. 1367–1374 
Curzon and Bridges, 1970 G. Curzon and P.K. Bridges, Tryptophan metabolism in depression, Journal of 
Neurology, Neurosurgery and Psychiatry 33 (1970), pp. 698–704 
Daya et al., 1989 S. Daya, K.O. Nonaka, G.R. Buzzel and J.R. Reiter, Heme precursor 5-aminolevulinic acid 
alters brain tryptophan and serotonin levels without changing pineal serotonin and melatonin concentrations, 
Journal of Neuroscience Research 23 (1989), pp. 304–309.  
Deguchi and Barchas, 1972 T. Deguchi and J. Barchas, Effect of chlorophenylalanine or hydroxylation of 
tryptophan in pineal and brain of rats, Molecular Pharmacology 8 (1972), pp. 770–779.  
Deumens et al., 2002 R. Deumens, A. Blokland and J. Prickaerts, Modeling Parkinson's disease in rats: an 
evaluation of 6-OHDA lesions of the nigrostriatal pathway, Experimental Neurology 175 (2002), pp. 303–317.  
Flower and Vane, 1972 R.J. Flower and J.R. Vane, Inhibition of prostaglandin synthetase in brain explains the 
anti-pyretic activity of paracetamol (4-acetamidophenol), Nature 240 (1972), pp. 410–411.  
Greengard et al., 1999 P. Greengard, A.C. Allen and A.C. Narin, Beyond the dopamine receptor: the DARPP-
32/protein phosphase-1 cascade, Neuron 23 (1999), pp. 435–447.  
Hardeland, 1997 R. Hardeland, New actions of melatonin and their relevance to biometeorology, International 
Journal of Biometeorology 41 (1997), pp. 47–57.  
Hardeland and Rensing, 1968 R. Hardeland and L. Rensing, Circadian oscillation in rat liver tryptophan pyrrolase 
and its analysis by substrate and hormone induction, Nature 219 (1968) (154), pp. 619–621 
Hardeland et al., 1995 R. Hardeland, I. Balzer, B. Poeggeler, B. Fuhrber, H. Uria, G. Behrmann, R. Wolf, T.J. 
Meyer and R.J. Reiter, On the primary functioning of melatonin in evolution: mediation of photoperiodic signals 
in a unicell, photooxidation, and scavenging of free radicals, Journal of Pineal Research 186 (1995), pp. 104–111  
Hayaishi, 1980 O. Hayaishi In: O. Hyaishi, Y. Ishimura and R. Kideo, Editors, Biochemical and Medical Aspects 
of Tryptophan Metabolism, Elservier/North-Holland, Amsterdam (1980), pp. 15–30.  
Kalivas and Stewart, 1991 P.W. Kalivas and Stewart, Dopamine transmission in the initiation and expression of 
drug- and stress-induced sensitization of motor activity, Brain Research Reviews 16 (1991), pp. 223–244.  
Kema et al., 2000 I.P. Kema, E.G de Vries and F.A. Muskiet, Clinical chemistry of serotonin and metabolites, 
Journal of Chromatography. B, Biomedical Sciences and Applications 74 (2000), pp. 33–48.  
Klein et al., 1997 D.C. Klein, S.L. Coon, P.H. Roseboom, J.L. Weller, M. Bernard, J.A. Gastel, M. Zatz, P.M. 
Luvone, I.R. Rodigues, V. Begay, J. Falcon, G. Cahill, V.M. Cassone and R. Baler, The melatonin rhythm-
generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland, Recent Progress in 
Hormone Research 52 (1997), pp. 307–357.  
Knable and Weinberger, 1997 M.B Knable and D.R. Weinberger, Dopamine, the prefrontal cortex and 
schizophrenia, Journal of Psychopharmacology 11 (1997), pp. 123–131.  
Koob, 1992 G.F. Koob, Drugs of abuse: anatomy, pharmacology and function of reward pathways, Trends in 
Pharmacology 13 (1992), pp. 177–184 
Koob and Le Moal, 1997 G.F. Koob and M. Le Moal, Drug abuse: hedonic homeostatic dysregulation, Science 
278 (1997), pp. 52–58.  
Langston et al., 1999 J.W. Langston, L.S. Forno, J. Tetrug, A.G. Reeves, J.A. Kaplan and D. Karlak, Evidence of 
active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-
tetrahydroxypyridine exposure, Annals of Neurology 46 (1999), pp. 598–605.  
Lovenberg et al., 1968 W. Lovenberg, E. Jequier and A. Sjoerdsma, Tryptophan hydroxylation in mammalian 
systems, Advances in Pharmacology 6 (1968), pp. 21–36.  
Lowry et al., 1951 O.H. Lowry, N.J. Rosebrough, A.L. Farr and R.J. Randall, Protein measurement with the folin 
phenol reagent, Journal of Biological Chemistry 193 (1951), pp. 265–275.  
McGeer, 1988 P.L. McGeer, S. Itagaki, B.E. Boyes and E.G. McGeer, Reactive microglia are positive for HLA-
DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology 38 (1988), pp. 1285–1291.  
Mohanakumar et al., 1995 K.P. Mohanakumar, S. Mohanty and D.K. Ganguly, Single neonatal administration of 
serotonin antiserum inhibits serotonin metabolism and function in adult rats, NeuroReport 7 (1995), pp. 238–240.  
Mohanakumar et al., 2000 K.P. Mohanakumar, D. Muralikrishnan and B. Thomas, Neuroprotection by sodium 
salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity, Brain Research 864 
(2000), pp. 281–290 
Muralikrishnan and Mohanakumar, 1998 D. Muralikrishnan and K.P. Mohanakumar, Neuroprotection by 
bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice, FASEB 12 
(1998), pp. 905–912.  
Murphy et al., 1986 P.J. Murphy, B.L. Myers and P. Badia, Nonsteroidal anti-inflammatory drugs alters body 
temperature and suppress melatonin in humans, Physiology and Behavior 69 (1986), pp. 133–139.  
Musajo and Benassi, 1964 L. Musajo and C.A. Benassi, Aspects of disorders of the kynurenine pathway of 
tryptophan metabolism in man, Advances in Clinical Chemistry 7 (1964), pp. 63–135  
Nestler and Aghajanian, 1997 E.J. Nestler and G.K. Aghajanian, Molecular and cellular basis of addiction, 
Science 278 (1997), pp. 58–63.  
Price et al., 1965 J.M. Price, R.R. Brown and N. Yess, Testing the functional capacity of the tryptophan–niacin 
pathway in man by analysis of urinary metabolites, Advances in Metabolic Disorders 2 (1965), pp. 159–225.  
Reiter, 1991 R.J. Reiter, Melatonin: that ubiquitously acting pineal hormone, News in Physiological Sciences 6 
(1991), pp. 223–227.  
Reiter, 1995 R.J. Reiter, The role of the neurohormone melatonin as a buffer against macromolecular oxidative 
damage, Neurochemistry International 27 (1995), pp. 453–460.  
Reiter, 1998 R.J. Reiter, Oxidative damage in the central nervous system: protection by melatonin, Progress in 
Neurobiology 56 (1998), pp. 359–384.  
Reiter et al., 1995 R.J. Reiter, D. Melchiorri, E. Sewerynek, B. Poeggler, L. Barlow-Walden, J. Chuang, G.G. 
Ortiz and D. Acuna-Casttroviejo, A review of the evidence supporting melatonin's role as an antioxidant, Journal 
of Pineal Research 18 (1995), pp. 1–11.  
Reiter et al., 1997 R.J. Reiter, J.M. Guerrero, G. Escames, M.A. Pappolla and D. Acuna-Castroviejo, Prophylactic 
actions of melatonin in oxidative neurotoxicity, Annals of the New York Academy of Sciences 825 (1997), pp. 70–
78  
Sairam et al., 2003 K. Sairam, K.S. Saravanan, R. Banerjee and K.P. Mohanakumar, Non-steroidal anti-
inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl 
pyridinium-induced dopaminergic neurotoxicity in rats, Brain Research 966 (2003), pp. 245–252.  
Shida et al., 1994 C.S. Shida, A.M. Castrucci and M.T. Lamy-Freund, High melatonin solubility in aqueous 
medium, Journal of Pineal Research 16 (1994), pp. 198–201 
Surrall et al., 1987 K. Surrall, J.A. Smith, H. Bird, B. Okala, H. Othman and D.J. Padwick, Effect of ibuprofen 
and indomethacin on human plasma melatonin, Journal of Pharmacy and Pharmacology 39 (1987), pp. 840–843.  
Szelenyi and Selmeczy, 2002 J. Szelenyi and Z. Selmeczy, Immunomodulatory effect of antidepressants, Current 
Opinion in Pharmacology 2 (2002), pp. 428–432 
Tan et al., 1993 D.X. Tan, L.D. Chen, B. Poeggler, L.C. Manchester and R.J. Reiter, Melatonin: a potent, 
endogenous hydroxyl radical scavenger, Endocrine Journal 1 (1993), pp. 57–60.  
van Praag, 1982 H.M. van Praag, Depression, suicide and the metabolism of serotonin in the brain, Journal of 
Affective Disorders 4 (1982), pp. 275–290.  
Vane, 1971 J.R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, 
Nature. New Biology 234 (1971), pp. 231–238.  
Voisin et al., 1993 P. Voisin, G. Van Camp, C. Pontoire and J.P. Collin, Prostaglandins stimulate serotonin 
acetylation in chick pineal cells: involvement of cyclic AMP-dependent and calcium/calmodulin-dependent 
mechanisms, Journal of Neurochemistry 60 (1993), pp. 666–670.  
Walsh and Daya, 1998 H.A. Walsh and S. Daya, Influence of the antidepressants desipramine and fluoxetine on 
tryptophan-2,3-dioxygenase in the presence of exogenous melatonin, Life Sciences 62 (1998), pp. 2417–2423.  
Williams and Goldman-Rakic, 1995 G.V. Williams and P.S. Goldman-Rakic, Modulation of memory fields by 
D1 receptors in prefrontal cortex, Nature 376 (1995), pp. 572–575.  
Wolf, 1974 H. Wolf, Studies on tryptophan metabolism in man, Scandinavian Journal of Clinical and Laboratory 
Investigation. Supplement 136 (1974), pp. 1–186.  
Xie et al., 1998 F. Xie, P. Wong, K. Yoshioka, R.G. Cooks and P.T. Kissinger, Journal of Liquid 
Chromatography and Related Technologies 21 (1998), p. 1273.  
Zar, 1974 J.H. Zar, Biostatistical Analysis, Prentice Hall, Engelwood Cliffs, NJ (1974), pp. 151–466 
 
 
 
